Your browser doesn't support javascript.
loading
Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology.
Lathuiliere, Aurelien; Vernet, Remi; Charrier, Emily; Urwyler, Muriel; Von Rohr, Olivier; Belkouch, Marie-Claude; Saingier, Valentin; Bouvarel, Thomas; Guillarme, Davy; Engel, Adrien; Salmon, Patrick; Laumonier, Thomas; Grogg, Julien; Mach, Nicolas.
Afiliación
  • Lathuiliere A; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.
  • Vernet R; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.
  • Charrier E; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland.
  • Urwyler M; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.
  • Von Rohr O; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland.
  • Belkouch MC; MaxiVAX SA, 1202 Geneva, Switzerland.
  • Saingier V; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.
  • Bouvarel T; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland.
  • Guillarme D; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.
  • Engel A; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland.
  • Salmon P; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.
  • Laumonier T; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland.
  • Grogg J; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.
  • Mach N; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland.
Mol Ther Methods Clin Dev ; 26: 441-458, 2022 Sep 08.
Article en En | MEDLINE | ID: mdl-36092361
ABSTRACT
Despite many promising results obtained in previous preclinical studies, the clinical development of encapsulated cell technology (ECT) for the delivery of therapeutic proteins from macrocapsules is still limited, mainly due to the lack of an allogeneic cell line compatible with therapeutic application in humans. In our work, we generated an immortalized human myoblast cell line specifically tailored for macroencapsulation. In the present report, we characterized the immortalized myoblasts and described the engineering process required for the delivery of functional therapeutic proteins including a cytokine, monoclonal antibodies and a viral antigen. We observed that, when encapsulated, the novel myoblast cell line can be efficiently frozen, stored, and thawed, which limits the challenge imposed by the manufacture and supply of encapsulated cell-based therapeutic products. Our results suggest that this versatile allogeneic cell line represents the next step toward a broader development and therapeutic use of ECT.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Ther Methods Clin Dev Año: 2022 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Ther Methods Clin Dev Año: 2022 Tipo del documento: Article País de afiliación: Suiza
...